Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
INO's Cash to Debt is ranked higher than
95% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. INO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
INO' s Cash to Debt Range Over the Past 10 Years
Min: 0.97  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.81
INO's Equity to Asset is ranked higher than
68% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INO: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
INO' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.81 Max: 0.95
Current: 0.81
0.44
0.95
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
95% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INO' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 9.42
M-Score: -1.23
WACC vs ROIC
23.32%
-183.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -95.06
INO's Operating margin (%) is ranked lower than
53% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. INO: -95.06 )
Ranked among companies with meaningful Operating margin (%) only.
INO' s Operating margin (%) Range Over the Past 10 Years
Min: -651  Med: -321.72 Max: -84.5
Current: -95.06
-651
-84.5
Net-margin (%) -61.24
INO's Net-margin (%) is ranked higher than
53% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. INO: -61.24 )
Ranked among companies with meaningful Net-margin (%) only.
INO' s Net-margin (%) Range Over the Past 10 Years
Min: -618.02  Med: -316.04 Max: -71.94
Current: -61.24
-618.02
-71.94
ROE (%) -16.18
INO's ROE (%) is ranked higher than
62% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. INO: -16.18 )
Ranked among companies with meaningful ROE (%) only.
INO' s ROE (%) Range Over the Past 10 Years
Min: -152.12  Med: -46.91 Max: -20.35
Current: -16.18
-152.12
-20.35
ROA (%) -13.66
INO's ROA (%) is ranked higher than
63% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. INO: -13.66 )
Ranked among companies with meaningful ROA (%) only.
INO' s ROA (%) Range Over the Past 10 Years
Min: -98.97  Med: -32.88 Max: -16.89
Current: -13.66
-98.97
-16.89
ROC (Joel Greenblatt) (%) -634.40
INO's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. INO: -634.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7552.88  Med: -3809.20 Max: -576.69
Current: -634.4
-7552.88
-576.69
Revenue Growth (3Y)(%) 69.90
INO's Revenue Growth (3Y)(%) is ranked higher than
91% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. INO: 69.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.3  Med: -6.85 Max: 163.7
Current: 69.9
-81.3
163.7
EBITDA Growth (3Y)(%) -9.10
INO's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. INO: -9.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.6  Med: -17.80 Max: 14.1
Current: -9.1
-34.6
14.1
EPS Growth (3Y)(%) -9.40
INO's EPS Growth (3Y)(%) is ranked lower than
56% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. INO: -9.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.3  Med: -16.25 Max: 33.5
Current: -9.4
-40.3
33.5
» INO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2014

INO Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
Q3 2015

INO Guru Trades in Q3 2015

Paul Tudor Jones 15,116 sh (New)
» More
Q4 2015

INO Guru Trades in Q4 2015

Joel Greenblatt 37,123 sh (New)
Jim Simons 392,781 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2016

INO Guru Trades in Q1 2016

Paul Tudor Jones 50,305 sh (New)
Joel Greenblatt Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ZIOP, NAS:FWP, NAS:PACB, OTCPK:BPMUF, NAS:MACK, OTCPK:SNBIF, NAS:SRPT, NAS:RLYP, NAS:ADRO, NAS:AMAG, NAS:FOLD, NAS:RGEN, NAS:ANIK, NAS:MGNX, NAS:DERM, NAS:EPZM, NAS:CEMP, NAS:ADAP, NAS:KERX, OTCPK:IPHYF » details
Traded in other countries:GBMB.Germany,
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

Inovio Pharmaceuticals Inc was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Genetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. ('VGX'), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio's wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the 'Merger'). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX's business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The Company is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive),

Ratios

vs
industry
vs
history
P/B 3.82
INO's P/B is ranked lower than
63% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. INO: 3.82 )
Ranked among companies with meaningful P/B only.
INO' s P/B Range Over the Past 10 Years
Min: 0.38  Med: 2.67 Max: 13.19
Current: 3.82
0.38
13.19
P/S 15.18
INO's P/S is ranked lower than
60% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. INO: 15.18 )
Ranked among companies with meaningful P/S only.
INO' s P/S Range Over the Past 10 Years
Min: 1.5  Med: 13.96 Max: 74.29
Current: 15.18
1.5
74.29
Current Ratio 4.81
INO's Current Ratio is ranked higher than
53% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. INO: 4.81 )
Ranked among companies with meaningful Current Ratio only.
INO' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 3.86 Max: 16.04
Current: 4.81
0.82
16.04
Quick Ratio 4.81
INO's Quick Ratio is ranked higher than
54% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. INO: 4.81 )
Ranked among companies with meaningful Quick Ratio only.
INO' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 3.73 Max: 16.04
Current: 4.81
0.82
16.04
Days Sales Outstanding 93.55
INO's Days Sales Outstanding is ranked lower than
70% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. INO: 93.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
INO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.24  Med: 69.76 Max: 116.74
Current: 93.55
6.24
116.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.24
INO's Price/Net Cash is ranked lower than
62% of the 691 Companies
in the Global Biotechnology industry.

( Industry Median: 4.99 vs. INO: 6.24 )
Ranked among companies with meaningful Price/Net Cash only.
INO' s Price/Net Cash Range Over the Past 10 Years
Min: 2.25  Med: 8.64 Max: 288
Current: 6.24
2.25
288
Price/Net Current Asset Value 5.49
INO's Price/Net Current Asset Value is ranked lower than
60% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. INO: 5.49 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.05  Med: 7.37 Max: 115.2
Current: 5.49
2.05
115.2
Price/Tangible Book 4.21
INO's Price/Tangible Book is ranked lower than
58% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. INO: 4.21 )
Ranked among companies with meaningful Price/Tangible Book only.
INO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.44  Med: 4.83 Max: 20.92
Current: 4.21
1.44
20.92
Price/Median PS Value 1.09
INO's Price/Median PS Value is ranked lower than
69% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. INO: 1.09 )
Ranked among companies with meaningful Price/Median PS Value only.
INO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.15 Max: 60.61
Current: 1.09
0.26
60.61
Earnings Yield (Greenblatt) (%) -7.90
INO's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. INO: -7.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.92  Med: 0.00 Max: 0
Current: -7.9
-18.92
0

More Statistics

Revenue (TTM) (Mil) $43.52
EPS (TTM) $ -0.38
Beta2.90
Short Percentage of Float16.44%
52-Week Range $4.50 - 11.69
Shares Outstanding (Mil)73.10

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 40 45 63
EPS ($) -0.65 -0.71 -0.59
EPS w/o NRI ($) -0.65 -0.71 -0.59
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for INO

Headlines

Articles On GuruFocus.com
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 

More From Other Websites
Here’s Why These Five Stocks Are on the Move Today Jun 22 2016
'Mad Money' Lightning Round: Be Patient on Alcoa Jun 22 2016
Full Show: What'd You Miss? (06/21) Jun 21 2016
Inovio CEO: Zika Vaccine Could Take a Few Years Jun 21 2016
Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study Jun 21 2016
Inovio Pharmaceuticals (INO) Optimistic on Zika/Ebola Vaccine Progress Jun 21 2016
We can rapidly move Zika and other vaccine studies forward: Inovio CEO Jun 21 2016
Leading the fight against Zika Jun 21 2016
[$$] Inovio Zika Vaccine Clear for Human Study Jun 21 2016
ETF’s with exposure to Inovio Pharmaceuticals, Inc. : June 20, 2016 Jun 20 2016
CNBC update: Orlando shooter 911 transcript Jun 20 2016
Experimental Zika vaccine to begin human testing Jun 20 2016
Experimental Zika vaccine to begin human testing Jun 20 2016
Why Are These Stocks in Spotlight on Monday? Jun 20 2016
FDA OKs human testing of Montco firm's experimental Zika virus vaccine Jun 20 2016
Inovio shares up 4.3% after Zika vaccine gets phase 1 trial approval Jun 20 2016
How Inovio Pharma Is Joining the Fight Against the Zika Virus Jun 20 2016
Inovio Pharma gets green signal to test Zika vaccine in human trial Jun 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)